

Yeong-Shiau Pu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3764590/publications.pdf>

Version: 2024-02-01

217
papers

6,022
citations

87723

38
h-index

110170

64
g-index

228
all docs

228
docs citations

228
times ranked

8203
citing authors

#	ARTICLE	IF	CITATIONS
1	Aristolochic acid-associated urothelial cancer in Taiwan. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8241-8246.	3.3	347
2	Resistance to Paclitaxel Is Proportional to Cellular Total Antioxidant Capacity. Cancer Research, 2005, 65, 8455-8460.	0.4	250
3	Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing. Science Translational Medicine, 2013, 5, 197ra102.	5.8	220
4	A Cullin3-KLHL20 Ubiquitin Ligase-Dependent Pathway Targets PML to Potentiate HIF-1 Signaling and Prostate Cancer Progression. Cancer Cell, 2011, 20, 214-228.	7.7	151
5	Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBP β expressions and suppressing NF- κ B activation. Prostate, 2002, 51, 211-218.	1.2	126
6	Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicology and Applied Pharmacology, 2007, 218, 99-106.	1.3	121
7	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	2.8	118
8	Negative Modulation of Androgen Receptor Transcriptional Activity by Daxx. Molecular and Cellular Biology, 2004, 24, 10529-10541.	1.1	109
9	Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes. International Journal of Cancer, 2013, 133, 14-20.	2.3	107
10	Changing trends of prostate cancer in Asia. Aging Male, 2004, 7, 120-132.	0.9	101
11	Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU International, 2007, 100, 281-286.	1.3	97
12	Biomonitoring of Aristolactam-DNA Adducts in Human Tissues Using Ultra-Performance Liquid Chromatography/Ion-Trap Mass Spectrometry. Chemical Research in Toxicology, 2012, 25, 1119-1131.	1.7	87
13	Ursolic acid derivatives induce cell cycle arrest and apoptosis in NTUB1 cells associated with reactive oxygen species. Bioorganic and Medicinal Chemistry, 2009, 17, 7265-7274.	1.4	82
14	Risk factors for prostate carcinoma in Taiwan. Cancer, 1999, 86, 484-491.	2.0	80
15	Podocalyxin EBP50 Ezrin Molecular Complex Enhances the Metastatic Potential of Renal Cell Carcinoma Through Recruiting Rac1 Guanine Nucleotide Exchange Factor ARHGAP7. American Journal of Pathology, 2010, 176, 3050-3061.	1.9	79
16	Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate, 2004, 60, 120-129.	1.2	76
17	Polymorphisms inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy. Clinical Cancer Research, 2011, 17, 928-936.	3.2	74
18	Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. BMJ: British Medical Journal, 2019, 367, l5919.	2.4	72

#	ARTICLE	IF	CITATIONS
19	Urinary 8-hydroxydeoxyguanosine and urothelial carcinoma risk in low arsenic exposure area. <i>Toxicology and Applied Pharmacology</i> , 2008, 226, 14-21.	1.3	69
20	Aristolochic Acid in the Etiology of Renal Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1600-1608.	1.1	65
21	Major Complications and Associated Risk Factors of Transrectal Ultrasound Guided Prostate Needle Biopsy: A Retrospective Study of 1875 Cases in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2007, 106, 929-934.	0.8	64
22	Washout gradient in dynamic contrast-enhanced MRI is associated with tumor aggressiveness of prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 912-919.	1.9	63
23	Transcriptional up-regulation of SOD1 by CEBPD: A potential target for cisplatin resistant human urothelial carcinoma cells. <i>Biochemical Pharmacology</i> , 2010, 80, 325-334.	2.0	59
24	Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. <i>Prostate</i> , 2011, 71, 1189-1197.	1.2	57
25	Expressions of E-Cadherin and Exon V6-Containing Isoforms of CD44 and their Prognostic Values in Human Transitional Cell Carcinoma. <i>Journal of Urology</i> , 1995, 153, 2025-2028.	0.2	54
26	CKD as a Risk Factor for Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. <i>American Journal of Kidney Diseases</i> , 2007, 50, 743-753.	2.1	52
27	MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies. <i>Cancer Letters</i> , 2015, 363, 127-136.	3.2	51
28	Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. <i>International Journal of Cancer</i> , 2006, 119, 1902-1907.	2.3	49
29	Plasma folate level, urinary arsenic methylation profiles, and urothelial carcinoma susceptibility. <i>Food and Chemical Toxicology</i> , 2008, 46, 929-938.	1.8	49
30	Predictors of failure of conservative treatment among patients with emphysematous pyelonephritis. <i>BMC Infectious Diseases</i> , 2014, 14, 418.	1.3	46
31	RBMV, a male germ cell-specific RNA-binding protein, activated in human liver cancers and transforms rodent fibroblasts. <i>Oncogene</i> , 2004, 23, 5815-5822.	2.6	45
32	Polymorphisms in one-carbon metabolism pathway genes, urinary arsenic profile, and urothelial carcinoma. <i>Cancer Causes and Control</i> , 2010, 21, 1605-1613.	0.8	45
33	Ling-Zhi Polysaccharides Potentiate Cytotoxic Effects of Anticancer Drugs against Drug-Resistant Urothelial Carcinoma Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2010, 58, 8798-8805.	2.4	45
34	EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). <i>Archives of Toxicology</i> , 2015, 89, 591-605.	1.9	44
35	Mir-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 1563-1573.	1.2	44
36	Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer. <i>Journal of Hazardous Materials</i> , 2013, 262, 1139-1146.	6.5	43

#	ARTICLE	IF	CITATIONS
37	Prostate cancer in Taiwan: epidemiology and risk factors. <i>Journal of Developmental and Physical Disabilities</i> , 2000, 23, 34-36.	3.6	41
38	Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 307-314.	1.7	41
39	Arsenic trioxide as a novel anticancer agent against human transitional carcinoma—characterizing its apoptotic pathway. <i>Anti-Cancer Drugs</i> , 2002, 13, 293-300.	0.7	39
40	Clinical and pathological data of 10 malignant pheochromocytomas: Long-term follow up in a single institute. <i>International Journal of Urology</i> , 2007, 14, 181-185.	0.5	38
41	Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT/Overlo</i>	0.4	38
42	Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. <i>Biochemical Pharmacology</i> , 2006, 71, 751-760.	2.0	37
43	Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. <i>Anti-Cancer Drugs</i> , 2007, 18, 487-491.	0.7	37
44	Clinicopathological Characteristics and Survival Outcome of Arsenic Related Bladder Cancer in Taiwan. <i>Journal of Urology</i> , 2009, 181, 547-553.	0.2	37
45	A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 421-427.	0.8	37
46	Down-Regulation of Glucose-Regulated Protein (GRP) 78 Potentiates Cytotoxic Effect of Celecoxib in Human Urothelial Carcinoma Cells. <i>PLoS ONE</i> , 2012, 7, e33615.	1.1	37
47	18Î²-Glycyrrhetic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4274-4285.	1.4	36
48	MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma. <i>Scientific Reports</i> , 2015, 5, 16948.	1.6	36
49	Antioxidant xanthone derivatives induce cell cycle arrest and apoptosis and enhance cell death induced by cisplatin in NTUB1 cells associated with ROS. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 1222-1231.	2.6	35
50	DIFFERENTIAL EXPRESSION OF C-CAM CELL ADHESION MOLECULE IN PROSTATE CARCINOGENESIS IN A TRANSGENIC MOUSE MODEL. <i>Journal of Urology</i> , 1999, 162, 892-896.	0.2	34
51	Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. <i>Journal of Biomedical Science</i> , 2009, 16, 82.	2.6	34
52	Gene polymorphisms of glutathione S-transferase omega 1 and 2, urinary arsenic methylation profile and urothelial carcinoma. <i>Science of the Total Environment</i> , 2011, 409, 465-470.	3.9	33
53	Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma. <i>Chronobiology International</i> , 2016, 33, 210-219.	0.9	33
54	Emphysematous pyelonephritis: Clinical characteristics and prognostic factors. <i>International Journal of Urology</i> , 2014, 21, 277-282.	0.5	32

#	ARTICLE	IF	CITATIONS
55	Management of patients with advanced prostate cancer in the Asia Pacific region: <i>“real world”</i> ™ consideration of results from the Advanced Prostate Cancer Consensus Conference <sc>(APCCC)</sc> 2017. <i>BJU International</i> , 2019, 123, 22-34.	1.3	32
56	Prognostic Significance of <i>p53</i> and <i>X-ray Repair Cross-complementing Group 1</i> Polymorphisms on Prostate-Specific Antigen Recurrence in Prostate Cancer Post-Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2007, 13, 6632-6638.	3.2	31
57	Expression of Stathmin in Localized Upper Urinary Tract Urothelial Carcinoma: Correlations With Prognosis. <i>Urology</i> , 2009, 74, 1264-1269.	0.5	31
58	Clinical Outcomes in Patients Undergoing Laparoscopic Adrenalectomy for Unilateral Aldosterone Producing Adenoma: Partial Versus Total Adrenalectomy. <i>Journal of Endourology</i> , 2014, 28, 1103-1106.	1.1	31
59	Prediabetes Is Associated with an Increased Risk of Testosterone Deficiency, Independent of Obesity and Metabolic Syndrome. <i>PLoS ONE</i> , 2013, 8, e74173.	1.1	31
60	Malignant Ureteral Obstruction: Functional Duration of Metallic versus Polymeric Ureteral Stents. <i>PLoS ONE</i> , 2015, 10, e0135566.	1.1	31
61	Tamoxifen Enhances the Chemosensitivity of Bladder Carcinoma Cells. <i>Journal of Urology</i> , 1995, 154, 601-605.	0.2	30
62	Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. <i>Cancer Letters</i> , 1995, 89, 81-87.	3.2	30
63	Long-Term Outcome of Hand-Assisted Laparoscopic Radical Nephroureterectomy for Upper-Tract Urothelial Carcinoma: Comparison with Open Surgery. <i>Journal of Endourology</i> , 2007, 21, 595-599.	1.1	30
64	Effect of Urinary Total Arsenic Level and Estimated Glomerular Filtration Rate on the Risk of Renal Cell Carcinoma in a Low Arsenic Exposure Area. <i>Journal of Urology</i> , 2011, 185, 2040-2044.	0.2	30
65	Synthesis and biological evaluation of <i>2,5</i> -dimethoxychalcone derivatives as microtubule-targeted anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2089-2098.	1.4	29
66	Increased Upper and Lower Tract Urothelial Carcinoma in Patients with End-Stage Renal Disease: A Nationwide Cohort Study in Taiwan during 1997-2008. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	29
67	Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure. <i>Environmental Research</i> , 2014, 128, 57-63.	3.7	29
68	Expression of MDR-1 Gene in Transitional Cell Carcinoma and its Correlation with Chemotherapy Response. <i>Journal of Urology</i> , 1996, 156, 271-275.	0.2	28
69	Polymorphism of inflammatory genes and arsenic methylation capacity are associated with urothelial carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2013, 272, 30-36.	1.3	28
70	Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 442-448.	0.4	27
71	Cytotoxic and antioxidant constituents from <i>Garcinia subelliptica</i> . <i>Food Chemistry</i> , 2012, 135, 851-859.	4.2	27
72	Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma. <i>European Journal of Cancer</i> , 2013, 49, 1458-1466.	1.3	27

#	ARTICLE	IF	CITATIONS
73	Cytotoxicity of arsenic trioxide to transitional carcinoma cells. <i>Urology</i> , 2002, 60, 346-350.	0.5	26
74	Choosing the Ideal Length of a Double-Pigtail Ureteral Stent according to Body Height: Study Based on a Chinese Population. <i>Urologia Internationalis</i> , 2009, 83, 70-74.	0.6	26
75	Xanthine Oxidase Inhibitory Triterpenoid and Phloroglucinol from Guttiferaceous Plants Inhibit Growth and Induced Apoptosis in Human NTUB1 Cells through a ROS-Dependent Mechanism. <i>Journal of Agricultural and Food Chemistry</i> , 2011, 59, 407-414.	2.4	26
76	The effect of cigarette smoke and arsenic exposure on urothelial carcinoma risk is modified by glutathione S-transferase M1 gene null genotype. <i>Toxicology and Applied Pharmacology</i> , 2013, 266, 254-259.	1.3	26
77	Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 810-820.	1.9	26
78	Polymorphisms of Arsenic (+3 Oxidation State) Methyltransferase and Arsenic Methylation Capacity Affect the Risk of Bladder Cancer. <i>Toxicological Sciences</i> , 2018, 164, 328-338.	1.4	26
79	Comparison of arsenic methylation capacity and polymorphisms of arsenic methylation genes between bladder cancer and upper tract urothelial carcinoma. <i>Toxicology Letters</i> , 2018, 295, 64-73.	0.4	26
80	Clinical Outcome of Taiwanese Men With Metastatic Prostate Cancer Compared With Other Ethnic Groups. <i>Urology</i> , 2008, 72, 1287-1292.	0.5	25
81	The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area. <i>Toxicology and Applied Pharmacology</i> , 2011, 257, 349-355.	1.3	25
82	Metallic Ureteral Stents in Malignant Ureteral Obstruction: Clinical Factors Predicting Stent Failure. <i>Journal of Endourology</i> , 2014, 28, 729-734.	1.1	25
83	2-Methoxyestradiol Induces Mitotic Arrest, Apoptosis, and Synergistic Cytotoxicity with Arsenic Trioxide in Human Urothelial Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e68703.	1.1	25
84	Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide. <i>Anti-Cancer Drugs</i> , 2004, 15, 779-785.	0.7	24
85	Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens. <i>Urology</i> , 2007, 69, 479-484.	0.5	24
86	Long-Term Follow-up of Hand-Assisted Laparoscopic Radical Nephrectomy for Organ-Confined Renal Cell Carcinoma. <i>Urology</i> , 2007, 69, 652-655.	0.5	24
87	Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2007, 177, 84-89.	0.2	24
88	Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. <i>International Journal of Cancer</i> , 2012, 130, 876-884.	2.3	24
89	Levels of plasma selenium and urinary total arsenic interact to affect the risk for prostate cancer. <i>Food and Chemical Toxicology</i> , 2017, 107, 167-175.	1.8	24
90	Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma. <i>Cancer</i> , 2006, 106, 1269-1275.	2.0	23

#	ARTICLE	IF	CITATIONS
91	High incidence of and risk factors for metachronous bilateral upper tract urothelial carcinoma in Taiwan. <i>International Journal of Urology</i> , 2006, 13, 864-869.	0.5	22
92	Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2008, 232, 203-209.	1.3	22
93	Increased Risk of Urinary Tract Cancer in ESRD Patients Associated with Usage of Chinese Herbal Products Suspected of Containing Aristolochic Acid. <i>PLoS ONE</i> , 2014, 9, e105218.	1.1	21
94	Long-term low-dose exposure of human urothelial cells to sodium arsenite activates lipocalin-2 via promoter hypomethylation. <i>Archives of Toxicology</i> , 2014, 88, 1549-1559.	1.9	21
95	Antiandrogen Hepatotoxicity in Patients with Chronic Viral Hepatitis. <i>European Urology</i> , 1999, 36, 293-297.	0.9	20
96	Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. <i>Aging Male</i> , 2012, 15, 34-41.	0.9	20
97	Urinary total arsenic and 8-hydroxydeoxyguanosine are associated with renal cell carcinoma in an area without obvious arsenic exposure. <i>Toxicology and Applied Pharmacology</i> , 2012, 262, 349-354.	1.3	20
98	Set-up errors due to endorectal balloon positioning in intensity modulated radiation therapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2007, 84, 177-184.	0.3	19
99	Correlation between the Urine Profile of 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Metabolites and 7-Methylguanine in Urothelial Carcinoma Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3390-3395.	1.1	19
100	Metallic ureteral stents in malignant ureteral obstruction: short-term results and radiological features predicting stent failure in patients with non-urological malignancies. <i>World Journal of Urology</i> , 2014, 32, 729-736.	1.2	19
101	Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma. <i>Oncotarget</i> , 2016, 7, 45225-45236.	0.8	19
102	8-Oxoguanine DNA Glycosylase and MutY Homolog Are Involved in the Incision of Arsenite-Induced DNA Adducts. <i>Toxicological Sciences</i> , 2006, 95, 376-382.	1.4	18
103	Intermediate Follow-up of Hand-Assisted Retroperitoneoscopic Nephroureterectomy for Management of Upper Urinary Tract Urothelial Carcinoma: Comparison with Open Nephroureterectomy. <i>Urology</i> , 2007, 69, 1030-1034.	0.5	18
104	Characteristics of Female Non-muscle-Invasive Bladder Cancer in Taiwan: Association with Upper Tract Urothelial Carcinoma and End-Stage Renal Disease. <i>Urology</i> , 2008, 71, 1155-1160.	0.5	18
105	Robot-Assisted Laparoscopic Nephroureterectomy versus Hand-Assisted Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: A Matched Comparison Study. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	18
106	Prognostic Significance of Cyclin D1 Polymorphisms on Prostate-Specific Antigen Recurrence After Radical Prostatectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 492-499.	0.7	17
107	Chalcone Derivatives Inhibit Human Platelet Aggregation and Inhibit Growth in Human Bladder Cancer Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2014, 37, 1191-1198.	0.6	17
108	Celecoxib-Induced Cytotoxic Effect Is Potentiated by Inhibition of Autophagy in Human Urothelial Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e82034.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Antraquinone derivatives induce G2/M cell cycle arrest and apoptosis in NTUB1 cells. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 5670-5678.	1.4	16
110	Environmental tobacco smoke and arsenic methylation capacity are associated with urothelial carcinoma. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 554-560.	0.8	16
111	XRCC1 Arg194Trp and Arg399Gln polymorphisms and arsenic methylation capacity are associated with urothelial carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2014, 279, 373-379.	1.3	16
112	Anti-cancer effects of ursane triterpenoid as a single agent and in combination with cisplatin in bladder cancer. <i>European Journal of Pharmacology</i> , 2014, 740, 742-751.	1.7	16
113	The effect of tumor location on oncologic outcomes in patients with upper urinary tract urothelial carcinoma stratified by pathologic stage. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 4.e19-4.e25.	0.8	16
114	Advantage of early orchiopexy for undescended testis: Analysis of testicular growth percentage ratio in patients with unilateral undescended testicle. <i>Scientific Reports</i> , 2017, 7, 17476.	1.6	16
115	Adiponectin gene polymorphisms and obesity increase the susceptibility to arsenic-related renal cell carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2018, 350, 11-20.	1.3	16
116	The impact of primary location and age at orchiopexy on testicular atrophy for congenital undescended testis. <i>Scientific Reports</i> , 2019, 9, 9489.	1.6	16
117	Lymphovascular invasion predicts poor outcome of urothelial carcinoma of renal pelvis after nephroureterectomy. <i>BJU International</i> , 2009, 103, 1047-1051.	1.3	15
118	Xanthine oxidase inhibitory terpenoids of <i>Amentotaxus formosana</i> protect cisplatin-induced cell death by reducing reactive oxygen species (ROS) in normal human urothelial and bladder cancer cells. <i>Phytochemistry</i> , 2010, 71, 2140-2146.	1.4	15
119	Robot-assisted nephroureterectomy for upper tract urothelial carcinoma: the Taiwan Robot Urological Surgery Team (TRUST) experience. <i>World Journal of Surgical Oncology</i> , 2014, 12, 219.	0.8	15
120	Protective effects of plasma alpha-tocopherols on the risk of inorganic arsenic-related urothelial carcinoma. <i>Science of the Total Environment</i> , 2011, 409, 1039-1045.	3.9	14
121	Down-regulation of PKC ζ in renal cell carcinoma and its clinicopathological implications. <i>Journal of Biomedical Science</i> , 2012, 19, 39.	2.6	14
122	Primary Mucinous Adenocarcinoma of Renal Pelvis with Carcinoembryonic Antigen Production. <i>Urology</i> , 2008, 71, 984.e7-984.e8.	0.5	13
123	UBE2M-mediated p27Kip1 degradation in gemcitabine cytotoxicity. <i>Biochemical Pharmacology</i> , 2011, 82, 35-42.	2.0	13
124	Combined effects of DNA methyltransferase 1 and 3A polymorphisms and urinary total arsenic levels on the risk for clear cell renal cell carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2016, 305, 103-110.	1.3	13
125	Preliminary evidence of polymorphisms of cell cycle regulatory genes and their roles in urinary tract urothelial cancer susceptibility and prognosis in a Taiwan population. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 543.e7-543.e16.	0.8	13
126	CROSS-RESISTANCE AND COMBINED CYTOTOXIC EFFECTS OF PACLITAXEL AND CISPLATIN IN BLADDER CANCER CELLS. <i>Journal of Urology</i> , 2001, 165, 2082-2085.	0.2	12

#	ARTICLE	IF	CITATIONS
127	Comparative genomic hybridization study of arsenic-exposed and non-arsenic-exposed urinary transitional cell carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2008, 227, 229-238.	1.3	12
128	Phloroglucinols Inhibit Chemical Mediators and Xanthine Oxidase, and Protect Cisplatin-Induced Cell Death by Reducing Reactive Oxygen Species in Normal Human Urothelial and Bladder Cancer Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2009, 57, 8782-8787.	2.4	12
129	Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: a comparison with other ethnic groups. <i>Aging Male</i> , 2010, 13, 10-17.	0.9	12
130	Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey. <i>International Journal of Urology</i> , 2019, 26, 1121-1127.	0.5	12
131	United in Fight against prostate cancer (UFO) registry: first results from a large, multi-centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia. <i>BJU International</i> , 2020, 125, 541-552.	1.3	12
132	Effect of diabetes mellitus and glycemic control on the prognosis of non-muscle invasive bladder cancer: a retrospective study. <i>BMC Urology</i> , 2020, 20, 117.	0.6	12
133	Polymorphism of nucleotide binding domain-like receptor protein 3 (NLRP3) increases susceptibility of total urinary arsenic to renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 6640.	1.6	12
134	Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma. <i>Oncotarget</i> , 2017, 8, 23787-23802.	0.8	12
135	Androgen receptor gene polymorphism may affect the risk of urothelial carcinoma. <i>Journal of Biomedical Science</i> , 2008, 15, 261-269.	2.6	11
136	Arsenic Methylation Capability, Myeloperoxidase and Sulfotransferase Genetic Polymorphisms, and the Stage and Grade of Urothelial Carcinoma. <i>Urologia Internationalis</i> , 2009, 82, 227-234.	0.6	11
137	Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 872-878.	0.8	11
138	Diffusion MRI predicts transrectal ultrasound biopsy results in prostate cancer detection. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 33, 356-363.	1.9	11
139	Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 323-330.	0.8	11
140	Prostate Health Index Density Outperforms Prostate Health Index in Clinically Significant Prostate Cancer Detection. <i>Frontiers in Oncology</i> , 2021, 11, 772182.	1.3	11
141	Paragangliomas of the urinary bladder: A report of 6 cases and review of the literature. <i>Urological Science</i> , 2015, 26, 111-114.	0.2	10
142	Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0145410.	1.1	10
143	Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 317-325.	1.1	10
144	Arsenic Methylation Capability, Heme Oxygenase-1 and NADPH Quinone Oxidoreductase-1 Genetic Polymorphisms and the Stage and Grade of Urothelial Carcinomas. <i>Urologia Internationalis</i> , 2008, 80, 405-412.	0.6	9

#	ARTICLE	IF	CITATIONS
145	Low ratio of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol-glucuronides (NNAL-Gluc)/free NNAL increases urothelial carcinoma risk. <i>Science of the Total Environment</i> , 2011, 409, 1638-1642.	3.9	9
146	4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes gene polymorphisms, NNK metabolites levels and urothelial carcinoma. <i>Toxicology Letters</i> , 2013, 216, 16-22.	0.4	9
147	A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 689-696.	0.8	9
148	The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma. <i>Toxicology and Applied Pharmacology</i> , 2017, 332, 1-7.	1.3	9
149	MLN4924, a Novel NEDD8-activating enzyme inhibitor, exhibits antitumor activity and enhances cisplatin-induced cytotoxicity in human cervical carcinoma: in vitro and in vivo study. <i>American Journal of Cancer Research</i> , 2015, 5, 3350-62.	1.4	9
150	Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 659-661.	0.8	8
151	Long-Term Outcome of Hand-Assisted Laparoscopic Nephroureterectomy for Pathologic T3 Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Endourology</i> , 2009, 23, 75-80.	1.1	8
152	Joint Effect of Arsenic Methylation Profile and NNK Metabolites on Urothelial Carcinoma. <i>Journal of Urology</i> , 2012, 188, 1701-1705.	0.2	8
153	Proactive rectal warming during total-gland prostate cryoablation. <i>Cryobiology</i> , 2014, 68, 431-435.	0.3	8
154	Polymorphisms of human 8-oxoguanine DNA glycosylase 1 and 8-hydroxydeoxyguanosine increase susceptibility to arsenic methylation capacity-related urothelial carcinoma. <i>Archives of Toxicology</i> , 2016, 90, 1917-1927.	1.9	8
155	Polymorphisms of TNF- α -308 G/A and IL-8 -251 T/A Genes Associated with Urothelial Carcinoma: A Case-Control Study. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	8
156	The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 260-267.	0.8	8
157	Nuclear Factor- κ B Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1954.	1.0	8
158	Effect of plasma selenium, red blood cell cadmium, total urinary arsenic levels, and eGFR on renal cell carcinoma. <i>Science of the Total Environment</i> , 2021, 750, 141547.	3.9	8
159	Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer. <i>Anticancer Research</i> , 2006, 26, 375-8.	0.5	8
160	Expression and androgen regulation of C-CAM cell adhesion molecule isoforms in rat dorsal and ventral prostate. <i>Oncogene</i> , 1999, 18, 3252-3260.	2.6	7
161	Systemic therapy for metastatic urothelial carcinoma. <i>BJU International</i> , 2008, 101, 795-803.	1.3	7
162	Comparison of 6- and 12-Core Prostate Biopsy in Taiwanese Men: Impact of Total Prostate-Specific Antigen, Prostate-Specific Antigen Density and Prostate Volume on Prostate Cancer Detection. <i>Urologia Internationalis</i> , 2009, 82, 270-275.	0.6	7

#	ARTICLE	IF	CITATIONS
163	Effectiveness of different diagnostic tools for upper urinary tract urothelial carcinoma. <i>Urological Science</i> , 2015, 26, 57-60.	0.2	7
164	Volume alteration of undescended testes: Before and after orchiopexy. <i>Urological Science</i> , 2016, 27, 161-165.	0.2	7
165	Far infrared radiation promotes rabbit renal proximal tubule cell proliferation and functional characteristics, and protects against cisplatin-induced nephrotoxicity. <i>PLoS ONE</i> , 2017, 12, e0180872.	1.1	7
166	Trifecta outcome of ureteral reconstruction in iatrogenic injury and non-iatrogenic ureteral lesions: a 10-year experience at a tertiary referral center. <i>World Journal of Urology</i> , 2019, 37, 1949-1957.	1.2	7
167	Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. <i>Advances in Therapy</i> , 2022, 39, 2641-2656.	1.3	7
168	Comparison Between Hand-assisted Laparoscopic and Retroperitoneoscopic Nephroureterectomy for the Management of Upper Urinary Tract Urothelial Carcinoma: Analysis of an Intermediate Follow-up Period. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2008, 18, 49-53.	0.4	6
169	Using age-referenced prostate-specific antigen percentile to predict survival outcomes in screened Taiwanese men. <i>International Journal of Cancer</i> , 2013, 132, 1927-1932.	2.3	6
170	Active Tuberculosis During Temsirolimus and Bevacizumab Treatment. <i>Journal of Clinical Oncology</i> , 2013, 31, e18-e20.	0.8	6
171	Laparoscopic Radical Prostatectomy Monotherapy, a More Aggressive Yet Less Invasive Option, Is Oncologically Effective in Selected Men with High-Risk Prostate Cancer Having Only One D'Amico Risk Factor: Experience from an Asian Tertiary Referral Center. <i>Journal of Endourology</i> , 2014, 28, 165-171.	1.1	6
172	Ureteral Involvement and Diabetes Increase the Risk of Subsequent Bladder Recurrence after Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	6
173	Prognostic value of saturated prostate cryoablation for localized prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 1487-1494.	1.2	6
174	Characteristics of arsenic-related bladder cancer: A study from Nationwide Cancer Registry Database in Taiwan. <i>Urological Science</i> , 2015, 26, 103-108.	0.2	6
175	Diagnostic Value of Finger-guided Prostate Nodule Biopsy Combined With Systemic Random Biopsy. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 713-718.	0.8	5
176	CROSS-RESISTANCE AND COMBINED CYTOTOXIC EFFECTS OF PACLITAXEL AND CISPLATIN IN BLADDER CANCER CELLS. <i>Journal of Urology</i> , 2001, 165, 2082-2085.	0.2	5
177	Enhanced suppression of prostate tumor growth by combining C-CAM1 gene therapy and angiogenesis inhibitor TNP-470. <i>Anti-Cancer Drugs</i> , 2002, 13, 743-749.	0.7	4
178	Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 207-213.	0.8	4
179	Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy. <i>PLoS ONE</i> , 2014, 9, e105091.	1.1	4
180	The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer. <i>World Journal of Surgical Oncology</i> , 2015, 13, 312.	0.8	4

#	ARTICLE	IF	CITATIONS
181	The joint effects of arsenic and risk diplotypes of insulin-like growth factor binding protein-3 in renal cell carcinoma. <i>Chemosphere</i> , 2016, 154, 90-98.	4.2	4
182	Perioperative changes in TGF- β 1 levels predict the oncological outcome of cryoablation-receiving patients with localized prostate cancer. <i>Cryobiology</i> , 2016, 73, 63-68.	0.3	4
183	Adjuvant androgen-deprivation therapy following prostate total cryoablation in high-risk localized prostate cancer patients â€” Open-labeled randomized clinical trial. <i>Cryobiology</i> , 2018, 82, 88-92.	0.3	4
184	Development of a chitosanâ€based tissueâ€engineered renal proximal tubule conduit. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2018, 106, 9-20.	1.6	4
185	Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy. <i>Scientific Reports</i> , 2020, 10, 776.	1.6	4
186	Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy. <i>Cancers</i> , 2021, 13, 2672.	1.7	4
187	Impact of high-volume disease in Asian population with newly diagnosed metastatic prostate cancer. <i>Urological Science</i> , 2018, 29, 136.	0.2	4
188	Megestrol acetate antagonizes cisplatin cytotoxicity. <i>Anti-Cancer Drugs</i> , 1998, 9, 733-738.	0.7	3
189	Ketoconazole in Taiwanese castration-resistant prostate cancer patients: Evaluation of response rates, durations, and predictors. <i>Urological Science</i> , 2012, 23, 48-51.	0.2	3
190	Analysis of transrectal and suprapubic ultrasonography for prostate size evaluation. <i>Urological Science</i> , 2017, 28, 166-168.	0.2	3
191	Oncological Outcomes of High-Risk Prostate Cancer Patients between Robot-Assisted Laparoscopic Radical Prostatectomy and Laparoscopic Radical Prostatectomy in Taiwan. <i>Urological Science</i> , 2018, 29, 43-48.	0.2	3
192	Quantitative analysis of messenger ribonucleic acid encoding natriuretic peptide receptors in aldosterone-producing adenoma. <i>Molecular and Cellular Endocrinology</i> , 1995, 111, 139-146.	1.6	2
193	Pneumopelvis, pneumoureter and pneumobladder. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 199-200.	0.2	2
194	Pretreatment prostate specific antigen (PSA) and 2-year PSA dynamics: Early predictors of prostate cancer prognosis with external radiation therapy. <i>Urological Science</i> , 2013, 24, 120-123.	0.2	2
195	Reply to S. Vale. <i>Journal of Clinical Oncology</i> , 2013, 31, 2634-2635.	0.8	2
196	XRCC1 Polymorphisms and Urinary 8-Hydroxydeoxyguanine Levels Are Associated with Urothelial Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0124066.	1.1	2
197	Increased Risk of New-Onset Hypertension After Shock Wave Lithotripsy in Urolithiasis. <i>Hypertension</i> , 2017, 70, 721-728.	1.3	2
198	The effectiveness and durability of ureteral tumor stent, the National Taiwan University Hospital experience. <i>Urological Science</i> , 2017, , .	0.2	2

#	ARTICLE	IF	CITATIONS
199	Tumor location on MRI determines outcomes of patients with prostate cancer after total prostate cryoablation. <i>Cryobiology</i> , 2021, 98, 39-45.	0.3	2
200	Outcomes of prostate atypical small acinar proliferation and high-grade prostate intraepithelial neoplasm patients. <i>Urological Science</i> , 2018, 29, 161.	0.2	2
201	Programmed Death-1 and Programmed Death Ligand-1 Blockade for Advanced Urothelial Carcinoma. <i>Urological Science</i> , 2019, 30, 2-7.	0.2	2
202	The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients. <i>Urological Science</i> , 2016, 27, 218-222.	0.2	1
203	Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study. <i>BMJ Open</i> , 2017, 7, e012950.	0.8	1
204	Oncological outcomes of high risk prostate cancer patients between robot-assisted laparoscopic radical prostatectomy and laparoscopic radical prostatectomy in Taiwan. <i>Urological Science</i> , 2017, , .	0.2	1
205	Long-term outcomes of nephrectomy and inferior vena cava thrombectomy in patients with advanced renal cell carcinoma: A single-center experience. <i>Urological Science</i> , 2017, , .	0.2	1
206	Outcomes of stratified transurethral resection of bladder tumor: A propensity score-matched analysis. <i>Journal of the Formosan Medical Association</i> , 2021, 121, 73-73.	0.8	1
207	Extranodal Extension Predicts Poor Survival Outcomes among Patients with Bladder Cancer. <i>Cancers</i> , 2021, 13, 4108.	1.7	1
208	Arsenics and Urothelial Carcinoma. , 2011, , 51-64.		1
209	Expression of human leukocyte antigen-a and b2-microglobulin in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16550-e16550.	0.8	1
210	Long-term outcomes of nephrectomy and inferior vena cava thrombectomy in patients with advanced renal cell carcinoma: A single-center experience. <i>Urological Science</i> , 2018, 29, 49.	0.2	1
211	An Unusual Presentation of Prostate Adenocarcinoma Metastatic to the Oral Cavity. <i>Urological Science</i> , 2011, 22, 83-85.	0.2	0
212	Prognostic significance of genetic polymorphisms on prostate-specific antigen recurrence after a radical prostatectomy. <i>Urological Science</i> , 2012, 23, 35-41.	0.2	0
213	Long-term oncologic outcomes of hand-assisted retroperitoneoscopic radical nephrectomy to treat clinically localized renal cell carcinoma. <i>Journal of the Formosan Medical Association</i> , 2012, 111, 41-45.	0.8	0
214	Antagonistic effect of N-ethylmaleimide on arsenic-mediated oxidative stress-induced poly(ADP-ribose)ylation and cytotoxicity. <i>Journal of Applied Toxicology</i> , 2017, 37, 573-582.	1.4	0
215	Comparative analysis between radical cystectomy and trimodality therapy for clinical stage II bladder cancer – Experience from a tertiary referral center. <i>Urological Science</i> , 2017, , .	0.2	0
216	Comparative Analysis between Radical Cystectomy and Trimodality Therapy for Clinical Stage II Bladder Cancer. <i>Urological Science</i> , 2018, 29, 25-32.	0.2	0

#	ARTICLE	IF	CITATIONS
217	The comparison of efficacy between the connaught and TICE strains of bacillus calmette-guerin in patients with non-muscle-invasive bladder cancer in Taiwan. Urological Science, 2022, .	0.2	0